Is GSK prepping a $1bn takeover bid for IDRx? | pharmaphorum
23 hours ago · GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...
GSK, Pfizer RSV shots must warn about rare paralysis risk
1 day ago · Pfizer and GSK vaccines will now be required to carry warnings that they may be tied to an increased risk of a rare neurological side effect. Photo by Beata Zawrzel/NurPhoto via Getty Images Rankings
GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 ...
1 day ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial ...
GSK nears $1bn deal for biotech developing drug for rare tumour
1 day ago · GSK nears $1bn deal for biotech developing drug for rare tumour ... Share News Tips Securely Individual Subscriptions Professional Subscriptions Republishing Executive Job Search Advertise with ...
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
FDA Grants Breakthrough Therapy Designation To GSK's …
3 days ago · (RTTNews) - GSK plc (GSK, GSK.L) said that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for GSK5764227, its B7-H3-targeted antibody-drug conjugate (ADC) being ...
Next stage in GSK’s Zantac defense gets underway today
2 days ago · A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients.
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
Get the latest GSK plc (GSK) stock news and headlines to help you in your trading and investing decisions.
GSK invests up to $800 million in Pennsylvania site, largest ...
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced its largest U.S. manufacturing investment to date. The up to $800 million investment will bring state-of-the-art drug substance manufacturing and additional drug product manufacturing capabilities to the company’s site in Marietta, Pennsylvania, along with over 200 new jobs.
Press releases | GSK US
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines. Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. Studies from OPERA and Trio cohorts provide further real-world evidence.